The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BTAI | -68.79% | -99.8% | -71.01% | -99% |
| S&P | +15.66% | +86.6% | +13.29% | +152% |
BioXcel Therapeutics, Inc. is a biopharmaceutical company, which engages in developing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. It also focuses on utilizing cutting-edge technology and research to develop therapeutics solutions. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
Major changes are afoot with the company, and few are happy about them.
BioXcel just announced a big change.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $98.00K | -54.2% |
| Gross Profit | $12.00K | 101.2% |
| Gross Margin | 12.24% | 495.0% |
| Market Cap | $50.30M | 94.2% |
| Market Cap / Employee | $1.36M | 0.0% |
| Employees | 37 | -50.0% |
| Net Income | -$30,911.00K | -126.5% |
| EBITDA | -$13,853.00K | -4.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $37.32M | -7.6% |
| Accounts Receivable | $0.00K | -100.0% |
| Inventory | 0.5 | -69.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $92.30M | -11.8% |
| Short Term Debt | $16.98M | 4515.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -145.62% | -50.5% |
| Return On Invested Capital | -243.19% | -102.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$18,787.00K | -15.0% |
| Operating Free Cash Flow | -$18,787.00K | -15.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -0.20 | -0.07 | -0.11 | -0.16 | -47.97% |
| Price to Sales | 8.02 | 5.30 | 16.35 | 48.33 | 325.37% |
| Price to Tangible Book Value | -2.97 | -0.07 | -0.11 | -0.16 | -97.03% |
| Enterprise Value to EBITDA | -9.11 | -8.64 | -6.68 | -7.82 | 15.09% |
| Return on Equity | -1766.9% | - | |||
| Total Debt | $102.95M | $105.91M | $108.94M | $109.29M | 4.11% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
